Recombinant cancer therapeutic cytokine

US9951114B2 · kind B2 · utility

Assignee

• Virginia Commonwealth University · US

Inventors

• Paul Fisher · Scarsdale, US
• Praveen Bhoopathi · Richmond, US
• Swadesh K. Das · Richmond, US
• Luni Emdad · Richmond, US
• Devanand Sarkar · Richmond, US
• Upneet Sokhi · Richmond, US

Key dates

• Filing date: Jun 4, 2014
• Grant date: Apr 24, 2018
• Expiry date: Jun 4, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N15/86
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Recombinant therapeutic cytokines (“therakines”) for the treatment of cancer are provided. The recombinant therakines include a truncated region of MDA-7/TL-24 (“M4”) not normally found in nature that has anti-cancer activity and a secretory signal which causes secretion of the therakine from plasmid/virus transduced normal and cancer cells and interaction of the therakine to MDA-7/IL-24 receptors on adjacent, neighboring and distant cancer cells. Therakine interaction results in bystander killing of the target cancer cell as well as adjacent, neighboring and distant cancer cells.